tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jul 20.
doi: 10.1002/jmv.28011. Online ahead of print.
Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience
Andrea De Vito[SUP] 1 [/SUP], Agnese Colpani[SUP] 1 [/SUP], Alessandra Bitti[SUP] 1 [/SUP], Beatrice Zauli[SUP] 1 [/SUP], Maria Chiara Meloni[SUP] 1 [/SUP], Marco Fois[SUP] 1 [/SUP], Lucia Denti[SUP] 1 [/SUP], Sara Bacciu[SUP] 1 [/SUP], Claudia Marcia[SUP] 1 [/SUP], Ivana Maida[SUP] 1 [/SUP], Sergio Babudieri[SUP] 1 [/SUP], Giordano Madeddu[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to cure Coronavirus Disease 2019 (COVID-19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N-hydroxycytidine with an in vitro e in vivo activity against SARS-CoV-2.
Methods: We conducted a retrospective cohort study including all people treated with Molnupiravir between the 10th of January and the 31th of March 2022 at the University Hospital of Sassari. Molnupiravir was prescribed, according to the Italian Agency of Drug indications, in patients with recent symptoms onset (≤5five days), no need of oxygen supplementation, and with a high risk of disease progression for the presence chronic diseases.
Results: We included 192 people with a mean age of 70.4±15.4 years; 144 (75%) patients were over 60 years. During the follow-up, 20 (10.4%) patients showed a disease progression. At the multivariate analysis, older age, having neurological disease, and having dyspnea at the onset of the symptoms, and acquiring SARS-CoV-2 infeciton during an hospital admission were associated with an increased risk of progression. On the contrary, early start of treatment was associated with a reduced risk of disease progression. Molnupiravir was also extremely safe since 13 (6.8%) adverse events were reported, with only one interruption.
Conclusion: Our study shows that Monlupiravir confirmed its efficacy and safety in a real-life cohort that included a high percentage of elderly people with a high comorbidity burden. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; COVID-19 treatment; SARS-CoV-2; antiviral treatment; early treatment; molnupiravir.
. 2022 Jul 20.
doi: 10.1002/jmv.28011. Online ahead of print.
Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience
Andrea De Vito[SUP] 1 [/SUP], Agnese Colpani[SUP] 1 [/SUP], Alessandra Bitti[SUP] 1 [/SUP], Beatrice Zauli[SUP] 1 [/SUP], Maria Chiara Meloni[SUP] 1 [/SUP], Marco Fois[SUP] 1 [/SUP], Lucia Denti[SUP] 1 [/SUP], Sara Bacciu[SUP] 1 [/SUP], Claudia Marcia[SUP] 1 [/SUP], Ivana Maida[SUP] 1 [/SUP], Sergio Babudieri[SUP] 1 [/SUP], Giordano Madeddu[SUP] 1 [/SUP]
Affiliations
- PMID: 35855627
- DOI: 10.1002/jmv.28011
Abstract
Introduction: Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to cure Coronavirus Disease 2019 (COVID-19) and prevent it. Molnupiravir is a ribonucleoside prodrug of N-hydroxycytidine with an in vitro e in vivo activity against SARS-CoV-2.
Methods: We conducted a retrospective cohort study including all people treated with Molnupiravir between the 10th of January and the 31th of March 2022 at the University Hospital of Sassari. Molnupiravir was prescribed, according to the Italian Agency of Drug indications, in patients with recent symptoms onset (≤5five days), no need of oxygen supplementation, and with a high risk of disease progression for the presence chronic diseases.
Results: We included 192 people with a mean age of 70.4±15.4 years; 144 (75%) patients were over 60 years. During the follow-up, 20 (10.4%) patients showed a disease progression. At the multivariate analysis, older age, having neurological disease, and having dyspnea at the onset of the symptoms, and acquiring SARS-CoV-2 infeciton during an hospital admission were associated with an increased risk of progression. On the contrary, early start of treatment was associated with a reduced risk of disease progression. Molnupiravir was also extremely safe since 13 (6.8%) adverse events were reported, with only one interruption.
Conclusion: Our study shows that Monlupiravir confirmed its efficacy and safety in a real-life cohort that included a high percentage of elderly people with a high comorbidity burden. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; COVID-19 treatment; SARS-CoV-2; antiviral treatment; early treatment; molnupiravir.